156 related articles for article (PubMed ID: 20515948)
1. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy.
Kremmidiotis G; Leske AF; Lavranos TC; Beaumont D; Gasic J; Hall A; O'Callaghan M; Matthews CA; Flynn B
Mol Cancer Ther; 2010 Jun; 9(6):1562-73. PubMed ID: 20515948
[TBL] [Abstract][Full Text] [Related]
2. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.
Flynn BL; Gill GS; Grobelny DW; Chaplin JH; Paul D; Leske AF; Lavranos TC; Chalmers DK; Charman SA; Kostewicz E; Shackleford DM; Morizzi J; Hamel E; Jung MK; Kremmidiotis G
J Med Chem; 2011 Sep; 54(17):6014-27. PubMed ID: 21774499
[TBL] [Abstract][Full Text] [Related]
4. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
[TBL] [Abstract][Full Text] [Related]
5. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
[TBL] [Abstract][Full Text] [Related]
6. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.
Rischin D; Bibby DC; Chong G; Kremmidiotis G; Leske AF; Matthews CA; Wong SS; Rosen MA; Desai J
Clin Cancer Res; 2011 Aug; 17(15):5152-60. PubMed ID: 21690571
[TBL] [Abstract][Full Text] [Related]
7. Combination of vascular disrupting agents and ionizing radiation.
Clémenson C; Chargari C; Deutsch E
Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
[TBL] [Abstract][Full Text] [Related]
8. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
[TBL] [Abstract][Full Text] [Related]
9. Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.
Liu L; O'Kelly D; Schuetze R; Carlson G; Zhou H; Trawick ML; Pinney KG; Mason RP
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925707
[TBL] [Abstract][Full Text] [Related]
10. Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105.
Bates D; Feris EJ; Danilov AV; Eastman A
Cancer Biol Ther; 2016; 17(3):291-9. PubMed ID: 26891146
[TBL] [Abstract][Full Text] [Related]
11. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin.
Gao F; Liang Y; Zhou P; Cheng J; Ding K; Wang Y
Eur J Med Chem; 2019 Sep; 178():177-194. PubMed ID: 31185410
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site.
Li W; Sun H; Xu F; Shuai W; Liu J; Xu S; Yao H; Ma C; Zhu Z; Xu J
Bioorg Chem; 2019 Apr; 85():49-59. PubMed ID: 30599412
[TBL] [Abstract][Full Text] [Related]
14. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ji YT; Liu YN; Liu ZP
Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
[TBL] [Abstract][Full Text] [Related]
15. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents.
Gourdeau H; Leblond L; Hamelin B; Desputeau C; Dong K; Kianicka I; Custeau D; Boudreau C; Geerts L; Cai SX; Drewe J; Labrecque D; Kasibhatla S; Tseng B
Mol Cancer Ther; 2004 Nov; 3(11):1375-84. PubMed ID: 15542776
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
17. [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Cai YC; Zou Y; Xian LJ
Yao Xue Xue Bao; 2010 Mar; 45(3):283-8. PubMed ID: 21351502
[TBL] [Abstract][Full Text] [Related]
18. Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis.
Banerjee S; Hwang DJ; Li W; Miller DD
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827858
[TBL] [Abstract][Full Text] [Related]
19. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
20. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
